What will happen if the patient stops taking sparsentane?

Sparsentan, this drug plays an important role in the treatment of primary immunoglobulinA nephropathy (IgAN). It uses its unique mechanism to help patients reduce proteinuria, thereby protecting kidney function and delaying disease progression. However, patients may face a range of repercussions when considering stopping taking sparsentane.

First, discontinuing sparsentane may result in a renewed increase in proteinuria levels. Sparsentane effectively reduces proteinuria by reducing inflammation and damage in the kidneys. Once the drug is stopped, the kidneys may be attacked again by the disease, causing proteinuria levels to rise again, which may accelerate the deterioration of kidney function.

Secondly, stopping the drug may affect the patient's blood pressure control. Sparsentane can often help patients lower blood pressure during treatment, especially for IgAN patients who also suffer from hypertension. After stopping the medication, blood pressure may rise again, increasing the risk of cardiovascular disease.

In addition, stopping spaxentan may cause other adverse effects. Some patients may experience side effects such as dizziness and fatigue during treatment with sparsentane. However, these side effects can usually be managed effectively with a doctor's guidance. If the patient stops taking the drug on his own, it may not only cause these side effects to reappear, but may also cause more serious problems, such as acute kidney injury.

Overall, discontinuing sparsentane may adversely affect a patient's condition. Therefore, before considering discontinuing medication, patients should fully communicate with their doctors, understand the possible consequences of discontinuing medication, and make decisions under the guidance of their doctors. At the same time, for those patients who really need to stop taking medication, doctors will also formulate corresponding monitoring and treatment plans to ensure the health and safety of the patients. Under no circumstances should patients stop taking sparsentane or change their treatment regimen on their own.